- ROUNDTABLE: Pharmacy’s future in sync with technology
- Prestige Brands solution to pediatric overdosing — unique squeezable, single-dose APAP packet
- FDA recommends health professionals prescribe no more than 325 mg of acetaminophen per dose
- FDA advisory committees vote against changing naproxen label to highlight a lower CVD profile
- New York's online database of drug prescriptions curtailing 'doctor shopping'
PARSIPPANY, N.J. — Watson Pharmaceuticals has launched its generic version of an opioid drug for treating pain, the company said Thursday.
Watson announced the Food and Drug Administration approval and launch of morphine sulfate extended-release capsules.
The drug is a generic version of Actavis' Kadian, which had sales of about $275 million during the 12-month period ended in September, according to IMS Health.